{"id":309,"date":"2026-02-18T16:25:17","date_gmt":"2026-02-18T14:25:17","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=309"},"modified":"2026-07-22T11:04:03","modified_gmt":"2026-07-22T08:04:03","slug":"tirzepatide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/","title":{"rendered":"Tirzepatid 10 mg"},"content":{"rendered":"<p>Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use. It acts on <strong>both GLP-1 and GIP receptors<\/strong> and has become a central reference compound in metabolic research, especially in models of <strong>appetite regulation, body-weight change, glycaemic control and incretin signalling<\/strong>.<\/p>\n<p>Tirzepatide belongs to a newer class of investigational metabolic peptides designed to engage <strong>more than one incretin pathway at the same time<\/strong>, rather than targeting GLP-1 alone. This dual-receptor profile makes it especially relevant in research focused on obesity, glucose homeostasis, insulin signalling, energy balance and next-generation metabolic therapeutics. Tirzepatide is supplied as a lyophilised vial for laboratory and analytical use only.<\/p>\n<h4><strong>What is Tirzepatide?<\/strong><\/h4>\n<p>Tirzepatide is an investigational <strong>dual incretin receptor agonist<\/strong> designed to activate two key receptor systems involved in metabolic regulation:<\/p>\n<ul>\n<li><strong>GLP-1 receptor<\/strong><\/li>\n<li><strong>GIP receptor<\/strong><\/li>\n<\/ul>\n<p>This receptor profile places Tirzepatide between <a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid <\/a>a <a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\">Retatrutid<\/a> in mechanistic breadth. Semaglutide primarily targets GLP-1 alone, while Retatrutide extends beyond GLP-1\/GIP into <strong>agonismus glukagonov\u00e9ho receptoru<\/strong>. Tirzepatide occupies the middle ground: broader than classical GLP-1 analogues, but more selective than triple agonists.<\/p>\n<p>Because of that positioning, Tirzepatide has become one of the most important benchmark compounds in current metabolic research. It is widely used as a comparison point in studies examining <strong>single-, dual- and triple-receptor incretin strategies<\/strong>. Lilly and peer-reviewed clinical literature consistently describe Tirzepatide as a <strong>once-weekly dual GIP\/GLP-1 receptor agonist<\/strong> with strong effects on glycaemic and body-weight outcomes in human studies.<\/p>\n<h4><strong>Why Tirzepatide matters in metabolic research<\/strong><\/h4>\n<p>Tirzepatide is important because it combines GLP-1 signalling with GIP receptor activity, creating a broader incretin profile than GLP-1 agonists alone while remaining more focused than triple agonists such as Retatrutide.<\/p>\n<p>In the literature, Tirzepatide has been studied in relation to:<\/p>\n<ul>\n<li>regulace t\u011blesn\u00e9 hmotnosti a signalizace chuti k j\u00eddlu<\/li>\n<li>metabolismus gluk\u00f3zy a glykemick\u00e9 markery<\/li>\n<li>insulin signalling and nutrient handling<\/li>\n<li>energy balance and systemic metabolic regulation<\/li>\n<li>comparative incretin research across GLP-1, dual agonist and triple agonist models<\/li>\n<\/ul>\n<p>For researchers building a metabolic peptide panel, Tirzepatide often serves as the central comparator molecule between Semaglutide and Retatrutide. It is one of the clearest examples of how expanding from a single-pathway GLP-1 agonist to a dual incretin agonist can change the metabolic profile under investigation. Your current page already points in this direction; the difference here is that we\u2019re making the comparison logic and search surface much more explicit.<\/p>\n<h4><strong>How Tirzepatide works<\/strong><\/h4>\n<p>Tirzepatide is designed to activate two receptor systems involved in metabolic control.<\/p>\n<p><strong>Aktivita GLP-1 receptoru<\/strong><\/p>\n<p>Signalizace GLP-1 je spojena se sn\u00ed\u017een\u00edm chuti k j\u00eddlu, opo\u017ed\u011bn\u00fdm vyprazd\u0148ov\u00e1n\u00edm \u017ealudku a podporou inzul\u00ednu z\u00e1vislou na gluk\u00f3ze. To je dr\u00e1ha, kterou v\u011bt\u0161ina v\u00fdzkumn\u00edk\u016f ji\u017e zn\u00e1 z l\u00e1tek, jako je semaglutid.<\/p>\n<p><strong>Aktivita GIP receptoru<\/strong><\/p>\n<p>GIP signalling is thought to influence insulin secretion, nutrient handling, adipose metabolism and the overall incretin response to food intake. In dual-agonist research, GIP activity is one of the major reasons Tirzepatide is mechanistically broader than GLP-1-only compounds.<\/p>\n<p><strong>Dual incretin profile<\/strong><\/p>\n<p>The combination of GLP-1 and GIP activity gives Tirzepatide a different metabolic profile from both Semaglutide and Retatrutide. Compared with Semaglutide, it expands the signalling scope beyond GLP-1 alone. Compared with Retatrutide, it remains more selective because it does not include glucagon receptor agonism.<\/p>\n<p>That makes Tirzepatide particularly useful in research focused on:<\/p>\n<ul>\n<li><strong>GLP-1 vs dual agonist comparisons<\/strong><\/li>\n<li><strong>body-weight and appetite outcomes<\/strong><\/li>\n<li><strong>glucose homeostasis and insulin dynamics<\/strong><\/li>\n<li><strong>the transition from single-pathway to multi-pathway incretin modulation<\/strong><\/li>\n<\/ul>\n<h4><strong>Published clinical findings on Tirzepatide<\/strong><\/h4>\n<p>Tirzepatide has become one of the most closely followed metabolic peptides because published human studies have reported <strong>substantial effects on body weight, glycaemic control and broader cardiometabolic markers<\/strong>. In the SURMOUNT-1 trial published in the <em>New England Journal of Medicine<\/em>, once-weekly Tirzepatide produced <strong>dose-dependent reductions in body weight<\/strong> over 72 weeks in adults with obesity or overweight, with the highest-dose arm showing some of the strongest weight-loss outcomes reported at the time for an incretin-based therapy.<\/p>\n<p>Tirzepatide has also shown strong glycaemic effects in type 2 diabetes research. In SURPASS-2, Tirzepatide was compared directly with once-weekly Semaglutide and demonstrated <strong>greater HbA1c reduction and greater weight reduction<\/strong> across the studied dose arms. Additional SURPASS studies have further established Tirzepatide as one of the key dual agonists in the current metabolic literature. Your current page already cites the most important trials \u2014 SURMOUNT-1, SURPASS-2 and related diabetes work \u2014 which is exactly the right evidence base for this section.<\/p>\n<p>Taken together, these trials are the main reason Tirzepatide is so often used as a reference point in modern obesity and diabetes research. It sits at the centre of the comparison between <strong>GLP-1 agonists, dual GLP-1\/GIP agonists, and newer triple agonist<\/strong> approaches.<\/p>\n<h4><strong>Publikovan\u00e9 v\u00fdsledky t\u00fdkaj\u00edc\u00ed se bezpe\u010dnosti a sn\u00e1\u0161enlivosti<\/strong><\/h4>\n<p>Published clinical studies on Tirzepatide indicate that the most commonly reported adverse events are gastrointestinal, especially <strong>nausea, diarrhoea, decreased appetite, vomiting and constipation<\/strong>. As with other incretin-based agents, these events were generally more common than with placebo and were often <strong>d\u00e1vkov\u011b z\u00e1visl\u00fd<\/strong>, particularly during the dose-escalation phase of treatment.<\/p>\n<p>Across the major clinical programs, most gastrointestinal events were described as <strong>m\u00edrn\u00fd a\u017e st\u0159edn\u00ed<\/strong> in severity, and discontinuation rates were still an important part of how Tirzepatide\u2019s overall profile was evaluated. This is one of the reasons published Tirzepatide research is typically discussed not only in terms of efficacy, but also in terms of <strong>sn\u00e1\u0161enlivost b\u011bhem eskalace<\/strong>, GI event burden and the balance between metabolic benefit and dropout risk.<\/p>\n<p>This section summarises <strong>published findings on investigational and clinical Tirzepatide research<\/strong>, not instructions or expectations for use of this product.<\/p>\n<h4><strong>Published dosing schedules used in Tirzepatide research<\/strong><\/h4>\n<p>Published Tirzepatide studies generally used <strong>once-weekly administration with stepwise dose escalation<\/strong> rather than starting at the final target dose immediately. In the major obesity and diabetes trials, Tirzepatide was typically studied at <strong>5 mg, 10 mg and 15 mg maintenance doses<\/strong>, with escalation from a lower starting dose over a period of weeks to improve tolerability. Your current reference list already points to the core trials that established this structure.<\/p>\n<p>In practical terms, the published research design for Tirzepatide is important because it shows that <strong>efficacy and tolerability were studied together<\/strong>. Researchers did not simply test \u201cone Tirzepatide dose\u201d; they tested staged escalation strategies leading to different maintenance doses. That is one of the reasons Tirzepatide remains such a useful comparator compound in metabolic peptide research.<\/p>\n<p><strong>Example of the maintenance-dose structure commonly used in major trials<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Published study context<\/th>\n<th align=\"right\">Initial dosing approach in the trial<\/th>\n<th align=\"right\">Maintenance dose arms studied<\/th>\n<th align=\"right\">Frekvence<\/th>\n<th align=\"right\">Duration<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Obesity \/ diabetes clinical trials<\/td>\n<td align=\"right\">stepwise escalation from lower starting dose<\/td>\n<td align=\"right\">5 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">varied by trial<\/td>\n<\/tr>\n<tr>\n<td>Obesity \/ diabetes clinical trials<\/td>\n<td align=\"right\">stepwise escalation from lower starting dose<\/td>\n<td align=\"right\">10 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">varied by trial<\/td>\n<\/tr>\n<tr>\n<td>Obesity \/ diabetes clinical trials<\/td>\n<td align=\"right\">stepwise escalation from lower starting dose<\/td>\n<td align=\"right\">15 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">varied by trial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Tyto rozvrhy jsou zahrnuty jako souhrn publikovan\u00e9ho n\u00e1vrhu v\u00fdzkumu a nejsou pokyny k pou\u017eit\u00ed tohoto produktu.<\/strong><\/p>\n<h4><strong>Tirzepatide vs Semaglutide vs Retatrutide<\/strong><\/h4>\n<p>Researchers often compare these three compounds because they sit on the same metabolic spectrum, but they are not interchangeable.<\/p>\n<p><strong>Tirzepatid<\/strong><\/p>\n<ul>\n<li><strong>Du\u00e1ln\u00ed agonista<\/strong>GLP-1 + GIP<\/li>\n<li>Central benchmark for dual incretin research<\/li>\n<li>\u010casto diskutov\u00e1no v souvislosti s <strong>body-weight outcomes, glycaemic control and incretin signalling<\/strong><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid<\/a><\/strong><\/p>\n<ul>\n<li><strong>Jedin\u00fd agonista<\/strong>GLP-1<\/li>\n<li>More selective and mechanistically narrower<\/li>\n<li>Spole\u010dn\u00fd referen\u010dn\u00ed bod pro <strong>V\u00fdzkum dr\u00e1hy GLP-1<\/strong><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\">Retatrutid<\/a><\/strong><\/p>\n<ul>\n<li><strong>Trojit\u00fd agonista<\/strong>GLP-1 + GIP + glukagon<\/li>\n<li>Broader receptor profile than Tirzepatide<\/li>\n<li>\u010casto diskutov\u00e1no v souvislosti s <strong>weight loss, energy expenditure and next-generation multi-pathway metabolic modulation<\/strong><\/li>\n<\/ul>\n<p>For researchers comparing incretin classes, Tirzepatide often functions as the <strong>middle reference point<\/strong> between single-pathway GLP-1 agonists and broader triple-agonist designs.<\/p>\n<h4><strong>Vlastnosti produktu<\/strong><\/h4>\n<p>Aplikace: laboratorn\u00ed a analytick\u00fd v\u00fdzkum<br \/>\nPou\u017eit\u00ed omezen\u00e9: nen\u00ed ur\u010deno k lidsk\u00e9 spot\u0159eb\u011b; pro l\u00e9ka\u0159sk\u00e9, veterin\u00e1rn\u00ed ani kosmetick\u00e9 pou\u017eit\u00ed<br \/>\nVyrobeno v za\u0159\u00edzen\u00edch spl\u0148uj\u00edc\u00edch spr\u00e1vnou v\u00fdrobn\u00ed praxi (GMP) za p\u0159\u00edsn\u00fdch protokol\u016f kontroly kvality.<br \/>\nKa\u017ed\u00e1 \u0161ar\u017ee je po v\u00fdrob\u011b pe\u010dliv\u011b laboratorn\u011b testov\u00e1na (Certifik\u00e1t o anal\u00fdze najdete pod obr\u00e1zky produkt\u016f).<br \/>\nLyofilizov\u00e1no (su\u0161eno mrazem) pro maxim\u00e1ln\u00ed stabilitu a prodlou\u017eenou trvanlivost.<br \/>\nUzav\u0159eno ve steriln\u00edch lahvi\u010dk\u00e1ch, p\u0159ipraveno k rekonstituci.<br \/>\nPurity: \u226599% (HPLC-tested)<br \/>\nAppearance: Lyophilized white\/off-white powder<br \/>\nMolekul\u00e1rn\u00ed vzorec: C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><br \/>\nMolecular weight: 4813.45<br \/>\nSequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-\u03b3-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2<br \/>\n<strong>\u00dalo\u017ei\u0161t\u011b<\/strong>Neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky jsou nejl\u00e9pe skladov\u00e1ny <strong>chlazen\u00e9 p\u0159i 2\u20138 \u00b0C<\/strong>, co\u017e je metoda skladov\u00e1n\u00ed potvrzen\u00e1 na\u0161\u00edm v\u00fdrobn\u00edm partnerem a vhodn\u00e1 a\u017e po dobu 24 m\u011bs\u00edc\u016f. Preferuje se chlazen\u00ed, proto\u017ee minimalizuje zbyte\u010dn\u00e9 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed b\u011bhem b\u011b\u017en\u00e9 manipulace. Pokud je vy\u017eadov\u00e1no podstatn\u011b del\u0161\u00ed skladov\u00e1n\u00ed, lze zmrazen\u00e9 uchov\u00e1vat i neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky. Po rekonstituci v\u017edy skladujte p\u0159i 2\u20138 \u00b0C a nezmrazujte.<\/p>\n<h4><strong>Nez\u00e1visl\u00e9 ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou<\/strong><\/h4>\n<p>Tato \u0161ar\u017ee pro\u0161la dodate\u010dn\u00fdm analytick\u00fdm ov\u011b\u0159en\u00edm t\u0159et\u00ed stranou prost\u0159ednictv\u00edm spole\u010dnosti Janoshik Analytical<br \/>\nBatch: TR10-260423<br \/>\nInternal HPLC purity: 99.13%<br \/>\nThird-party verification: 99.62% independently confirmed high purity and identity consistency. <a href=\"https:\/\/verify.janoshik.com\/tests\/166500-Tirzepatide_HZQXE7RE4JKV\" target=\"_blank\" rel=\"noopener\">Zobrazit ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou<\/a>.<\/p>\n<h4><strong>Rekonstituce a manipulace<\/strong><\/h4>\n<p>Tirzepatide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with <a href=\"https:\/\/life-peptide.com\/cs\/product\/bac-10-ml\/\">bakteriostatick\u00e1 voda<\/a> p\u0159ed pou\u017eit\u00edm. Peptidy t\u0159\u00eddy GLP-1 se n\u011bkdy rozpou\u0161t\u011bj\u00ed pomalu a vy\u017eaduj\u00ed velmi jemn\u00e9 rozpou\u0161t\u011bn\u00ed, aby se zabr\u00e1nilo p\u011bn\u011bn\u00ed nebo vzniku m\u00edrn\u00e9ho z\u00e1kalu.<\/p>\n<p>Pro dal\u0161\u00ed pokyny k v\u00fdb\u011bru rozpou\u0161t\u011bdla, pl\u00e1nov\u00e1n\u00ed koncentrac\u00ed a skladov\u00e1n\u00ed viz \u00fapln\u00e9 <a href=\"https:\/\/life-peptide.com\/cs\/reconstitution-of-peptides\/\">Pr\u016fvodce rekonstituc\u00ed peptid\u016f<\/a> a <a href=\"https:\/\/life-peptide.com\/cs\/calculator\/\">Kalkula\u010dka rekonstituce<\/a>.<\/p>\n<h4>Vybran\u00e9 v\u00fdzkumn\u00e9 reference<\/h4>\n<ul>\n<li>Jastreboff AM a kol. <em>\u201cTirzepatide Once Weekly for the Treatment of Obesity.\u201d New England Journal of Medicine<\/em>, 2022.<\/li>\n<li>Frias JP et al. <em>\u201cTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.\u201d New England Journal of Medicine<\/em>, 2021.<\/li>\n<li>Ludvik B et al. <em>\u201cOnce-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin.\u201d The Lancet<\/em>, 2021.<\/li>\n<li>Coskun T a kol. <em>\u201cLY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.\u201d Molecular Metabolism,<\/em> 2018.<\/li>\n<\/ul>\n<h4><strong>\u010casto kladen\u00e9 dotazy<\/strong><\/h4>\n<p><strong>What kind of peptide is Tirzepatide?<\/strong><\/p>\n<p>Tirzepatide is an investigational dual incretin agonist designed to activate GLP-1 and GIP receptors.<\/p>\n<p><strong>How is Tirzepatide different from Semaglutide?<\/strong><\/p>\n<p>Semaglutide primarily targets GLP-1 alone, while Tirzepatide combines GLP-1 and GIP receptor activity, giving it a broader incretin signalling profile.<\/p>\n<p><strong>How is Tirzepatide different from Retatrutide?<\/strong><\/p>\n<p>Retatrutide is a triple agonist that adds glucagon receptor activity to the GLP-1\/GIP profile. Tirzepatide remains more selective as a dual GLP-1\/GIP agonist.<\/p>\n<p><strong>What research areas is Tirzepatide associated with?<\/strong><\/p>\n<p>Tirzepatide has been studied in the literature in relation to body-weight outcomes, appetite regulation, glycaemic control, insulin signalling and incretin biology.<\/p>\n<p><strong>Je tento produkt ur\u010den k lidsk\u00e9mu pou\u017eit\u00ed?<\/strong><\/p>\n<p>Ne. Tento produkt je dod\u00e1v\u00e1n v\u00fdhradn\u011b pro v\u00fdzkumn\u00e9 \u00fa\u010dely a nen\u00ed ur\u010den k lidsk\u00e9 spot\u0159eb\u011b ani k terapeutick\u00e9mu pou\u017eit\u00ed.<\/p>\n<h4><strong>Souvisej\u00edc\u00ed v\u00fdzkumn\u00fd kontext<\/strong><\/h4>\n<p>Tirzepatide is part of the dual incretin receptor agonist (GLP-1\/GIP) metabolic research class. For mechanistic comparison with single-pathway GLP-1 agonists and triple-agonist compounds, see our <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Pr\u016fvodce v\u00fdzkumem metabolismu GLP-1<\/a>.<\/strong><\/p>\n<p>Proch\u00e1zet v\u0161echny slou\u010deniny v <a href=\"\/cs\/product-category\/metabolic-research\/\"><strong>Kategorie metabolick\u00e9ho v\u00fdzkumu.<\/strong><\/a><\/p>\n<p>V\u00fdzkumn\u00edci porovn\u00e1vaj\u00edc\u00ed aktivaci v\u00edce receptor\u016f mohou tak\u00e9 zkoumat:<\/p>\n<ul>\n<li data-start=\"2635\" data-end=\"2671\"><a href=\"http:\/\/example.test\/product\/retatrutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Retatrutide (GLP-1\/GIP\/glucagon triple-receptor agonist)<\/a><\/li>\n<li data-start=\"2674\" data-end=\"2702\"><a href=\"http:\/\/example.test\/product\/semaglutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Semaglutid (agonista receptoru GLP-1)<\/a><\/li>\n<\/ul>\n<p><strong>NOTE:<\/strong> This is for educational reference only and does not constitute medical advice.<\/p>\n<p><strong>Disclaimer:<\/strong><br \/>\nTento produkt je prod\u00e1v\u00e1n pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed ur\u010den k diagnostice, l\u00e9\u010db\u011b, vyl\u00e9\u010den\u00ed nebo prevenci jak\u00fdchkoli onemocn\u011bn\u00ed. Kupuj\u00edc\u00ed p\u0159eb\u00edr\u00e1 plnou odpov\u011bdnost za \u0159\u00e1dnou manipulaci a pou\u017eit\u00ed.<\/p>","protected":false},"excerpt":{"rendered":"<p>Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use. It acts on both GLP-1 and GIP receptors and has become a central reference compound in metabolic research, especially in models of appetite regulation, body-weight change, glycaemic control and incretin signalling.<\/p>\n<p>||<\/p>\n<p>\u010cistota \u226599% | Doprava v r\u00e1mci EU od 5 \u20ac | Mo\u017enost volby dopravy zdarma | P\u0159ij\u00edm\u00e1me platby kartou<\/p>","protected":false},"featured_media":1247,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,144,279,139,250,251,247,258,252,246],"class_list":["post-309","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-dual-agonist","product_tag-fat-loss-peptide","product_tag-glp-1-research","product_tag-glp-1-gip-agonist","product_tag-glucose-research","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-obesity-research","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product\/309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/comments?post=309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media\/1247"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media?parent=309"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_brand?post=309"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_cat?post=309"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_tag?post=309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}